HEALTH CARE:
PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
Aimmune Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing treatments to protect children with food allergies from accidental exposure. Aimmune Therapeutics serves customers worldwide.
| Market Cap | 1.456 Billion | Shares Outstanding | 50.86 Million | Avg Volume | 770.845 Thousand |
| 1-Yr BETA vs S&P TR | Current Ratio | 7.11 | Quick Ratio | 7.11 |
| Q2 2019 | All Institutions | Hedge Funds 1 |
|---|---|---|
| To trade AIMT now: | |
|
| Filers who had this stock in their top 10: | 4 | 0 (0.0%) |
| 13F Filers holding this stock: | 123 | 15 (1.55%) |
| Aggregate 13F shares on 06/30/2019: | 48.899 Million | 8.154 Million |
| Aggregate 13F shares on 03/31/2019: | 47.571 Million | 8.762 Million |
| Percent change: | 2.79% | -6.94% |
| Funds creating new positions: | 23 | 3 |
| Funds Adding to an existing position: | 48 | 6 |
| Funds closing out their position: | 22 | 5 |
| Funds reducing their position: | 27 | 4 |
| 1 hedge funds as identified by whalewisdom.com through public filings. | ||
View recent insider trading info
Aimmune Therapeutics Inc Chart by YCharts
Please sign in first
1.6 Thousand total shares from 1 transactions
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
4,282 | 2019-10-04 | 1 | |
|
0 | 2019-09-30 | 2 | |
|
|
2,942,500 | 2019-08-22 | 0 | |
|
HAUMANN BRETT K SVP CLIN DEV & CHIEF MED OFC |
|
233,968 | 2019-08-20 | 1 |
|
0 | 2019-06-19 | 1 | |
|
162,610 | 2019-06-13 | 1 | |
|
0 | 2019-06-13 | 1 | |
|
4,179 | 2019-06-13 | 1 | |
|
|
6,000 | 2019-06-12 | 1 | |
|
5,000 | 2019-06-10 | 0 | |
|
10,221 | 2019-05-23 | 1 | |
|
OXTOBY ANDREW CHIEF COMMERCIAL OFFICER |
|
12,000 | 2019-01-22 | 2 |
|
BARROWCLIFFE SUSAN E. GENERAL MANAGER, EUROPE |
|
9,375 | 2018-11-19 | 1 |
|
LONGITUDE CAPITAL PARTNERS II, LLC |
|
3,019,734 | 2018-07-02 | 0 |
|
No longer subject to file | 2018-06-25 | 0 | |
|
SHEEHY DOUGLAS T. SEE REMARKS |
|
33,079 | 2018-05-22 | 0 |
|
ROZENMAN MARY M. SEE REMARKS |
|
7,004 | 2018-03-04 | 0 |
|
KNAPP JEFFREY H CHIEF OPERATING OFFICER |
|
12,151 | 2018-03-04 | 0 |
|
ADELMAN DANIEL C MD CHIEF MEDICAL OFFICER |
|
9,375 | 2018-03-04 | 0 |
|
FORESITE CAPITAL MANAGEMENT II, LLC FORESITE CAPITAL FUND II, L.P. FORESITE CAPITAL MANAGEMENT III, LLC |
|
3,643,191 | 2017-05-26 | 0 |
|
DESOUZA WARREN L. CHIEF FINANCIAL OFFICER |
|
20,681 | 2017-04-03 | 0 |
|
7,552,084 | 2016-11-23 | 0 | |
|
ELFONT ROBERT MYLES CHIEF MEDICAL OFFICER |
|
299,002 | 2016-02-26 | 0 |
|
FORESITE CAPITAL MANAGEMENT II, LLC |
|
0 | 2015-08-05 | 0 |
|
RAFF HOWARD V. CHIEF OPERATING OFFICER |
|
428,575 | 2015-08-05 | 0 |
| Reporting Owners | Transaction Date | Transaction Code | Shares | Share Price | Acquired or Disposed | Shares Owned Following Transaction | Combined shares owned after filing | Direct/Indirect Ownership | 10b-5 |
|---|---|---|---|---|---|---|---|---|---|
| 2019-09-18 | P | 1,550 | $22.57 | a | 33,574 | 33,574.00 | direct | ||
| 2019-09-17 | A | 12,500 | $22.34 | a | 45,561 | 6,058,695.00 | direct |
